
Utilizing HiBiT TCK Bioassays To Validate Cell Therapy & mAb-Mediated Immunotherapy Potency

Speaker Presentation Hess Nicholas, Promega Corporation, 2024
Utilizing HiBiT TCK Bioassays To Validate Cell Therapy & mAb-Mediated Immunotherapy Potency
Utilizing HiBiT TCK Bioassays To Validate Cell Therapy & mAb-Mediated Immunotherapy Potency